In today’s trading session, three pharmaceutical companies received regulatory approvals from major health authorities, such as the United States Food and Drug Administration (USFDA) and the European Medicines Agency (EMA), leading to a surge in investor interest.
These approvals are important because they confirm that the company’s products are safe and effective, allowing them to be sold in more markets. Recently, several Indian pharma companies have caught attention after getting such approvals, which could help them grow their business.
Here’s a list of pharma stocks currently in focus due to recent regulatory green lights from the US and the EU
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd (formerly Cadila Healthcare) is a leading global pharmaceutical company headquartered in India. It focuses on manufacturing a wide range of generic medicines, including APIs, formulations, and biologics, with a strong presence in the US and European markets.
The company received regulatory approval following a surveillance inspection by the USFDA at its API manufacturing facility in Dabhasa, Gujarat. The inspection found some minor issues, but none were serious or related to data tampering. This means the facility meets safety and quality standards, which helps Zydus keep selling and expanding its products globally.
With a market capitalization of Rs. 89,117.11 crores on Monday, the shares of Zydus Lifesciences Ltd jumped upto 3.3 percent, making a high of Rs. 887.50 per share compared to its previous closing price of Rs. 859.10 per share.
Biocon Ltd
Biocon Ltd is India’s largest biopharmaceutical company, specializing in biologics, biosimilars, and generic formulations. The company, headquartered in Bangalore, is known for its expertise in biotechnology and offers a wide range of affordable drugs for oncology, diabetes, and autoimmune diseases.
Biocon Biologics, a part of Biocon, got a positive review from a key European health committee for two bone-related medicines (denosumab biosimilars). This is an important step before these drugs can be officially approved and sold across the European Union, helping Biocon grow its presence in global markets.
With a market capitalization of Rs. 38,455.22 crores on Monday, the shares of Biocon Limited jumped upto 3.3 percent, making a high of Rs. 322.45 per share compared to its previous closing price of Rs. 312.00 per share.
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd is a leading Indian multinational pharmaceutical company that manufactures generic drugs and active pharmaceutical ingredients (APIs). The company specializes in a wide array of therapeutic areas, including antibiotics, antiretrovirals, and oncology.
Aurobindo Pharma’s unit, CuraTeQ Biologics, received a positive opinion from a European health body for its breast cancer treatment drug, Dazublys. This is their third such approval in five months, bringing them closer to their goal of launching 10 biosimilar drugs by 2030, and the Final EU approval is expected by July 2025.
With a market capitalization of Rs. 72,545.03 crores on Monday, the shares of Aurobindo Pharma Ltd jumped upto 3.4 percent, making a high of Rs. 1259.50 per share compared to its previous closing price of Rs. 1217.85 per share.
Written by Sridhar J
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
